Bloodstream Infection Due to Multidrug-Resistant Organisms - Multicenter Study on Determinants of Clinical Outcomes (BLOOMY-COM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03578835|
Recruitment Status : Recruiting
First Posted : July 6, 2018
Last Update Posted : July 6, 2018
|Condition or disease|
|Bloodstream Infection Septic Shock|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||6000 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Bloodstream Infection Due to Multidrug-Resistant Organisms - Multicenter Study on Determinants of Clinical Outcomes|
|Actual Study Start Date :||February 1, 2017|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||June 30, 2019|
Multi-center BSI cohort
Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
- Short-term mortality due to bloodstream infection [ Time Frame: From index blood culture to discharge, an average of 16 days ]Mortality due to bloodstream infection up to hospital discharge in association to causative species, resistance pattern, comorbidities, complications etc.
- Long-term mortality due to bloodstream infection [ Time Frame: Up to 6 months ]Mortality due to bloodstream infection up to long-term follow-up after 6 months in association to causative species, resistance pattern, comorbidities, complications etc.
- Long-term morbidity due to bloodstream infection [ Time Frame: At 6 months ]Morbidity as measured by the SF-36 questionnaire due to bloodstream infection after 6 months in association to causative species, resistance pattern, comorbidities, complications etc.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03578835
|Contact: Evelina Tacconelli, Prof.||004970712983685||Evelina.Tacconelli@med.uni-tuebingen.de|
|Contact: Winfried Kern, Prof.||email@example.com|
|Tübingen, Bade-Württemberg, Germany, 72076|
|Freiburg, Baden-Württemberg, Germany, 79106|
|Gießen, Hessen, Germany, 35392|
|Köln, Nordrhein-Westfalen, Germany, 50931|
|Lübeck, Schleswig-Holstein, Germany, 23538|
|Charité - Universitätsmedizin Berlin||Recruiting|
|Berlin, Germany, 12203|